Staar Surgical Visian ICL
This article was originally published in The Gray Sheet
Executive Summary
Implantable contact lens PMA approval for myopia likely will be delayed beyond the Oct. 22 American Academy of Ophthalmologists meeting, the firm says, following Sept. 23 receipt of 36 "FDA 483" observations stemming from a re-inspection of its Monrovia, Calif. manufacturing facility. An initial inspection led to a December 2003 warning letter and subsequent Staar corrections. Current observations include quality system and complaint handling issues. Staar is preparing a written response and will undertake further corrective action (1"The Gray Sheet" Sept. 20, 2004, p. 3)...
You may also be interested in...
Staar Surgical strengthens RA
Eye product company hires James Farnworth as VP-quality, regulatory & clinical affairs Oct. 12. Farnworth will help resolve QSR compliance issues and trial monitoring violations cited at Staar's Monrovia, Calif. plant (1"The Gray Sheet" Oct. 4, 2004, In Brief). He formerly was director of regulatory affairs & quality assurance at Volcano Therapeutics. Quintiles still will be retained by Staar, whose Visian ICL intraocular lens awaits PMA approval...
AMO Cleared To Market Myopia IOL; Staar Surgical Awaits Site Re-Inspection
Ophtec/Advanced Medical Optics will start U.S. clinical trials next spring for a foldable version of their phakic intraocular lens to correct near-sightedness, building on two years of European study data
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.